

MERIDIAN BIOSCIENCE INC  
Form 8-K  
April 26, 2011

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 21, 2011

MERIDIAN BIOSCIENCE, INC.  
(Exact name of registrant as specified in its charter)

Ohio  
(State or other jurisdiction of  
incorporation)

0-14902  
(Commission File  
Number)

31-0888197  
(IRS Employer Identification  
No. )

3471 River Hills Drive, Cincinnati, Ohio  
(Address of principal executive offices)

45244  
(Zip Code)

Registrant's telephone number, including area code

(513) 271-3700

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 2.02. Results of Operations and Financial Condition.

On April 21, 2011, the Company issued a press release announcing its financial results for the fiscal quarter ended March 31, 2011. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 8.01. Other Events.

On April 21, 2011, the Company's Board of Directors appointed the following executives to the Meridian Bioscience, Inc. officer positions indicated, effectively immediately:

Marco G. Calzavara  
President and Managing Director, Meridian Bioscience Europe

Vecheslav A. Elagin  
Vice President, Research and Development

Marvienne D. Johnson  
Vice President, Human Resources

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated April 21, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERIDIAN BIOSCIENCE, INC.

Date: April 26, 2011

By: /s/ Melissa A. Lueke  
Melissa A. Lueke  
Executive Vice President and Chief  
Financial Officer  
(Principal Accounting Officer)